MAIA Biotechnology, Inc. (MAIA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MAIA SEC filings page.
This page shows MAIA Biotechnology, Inc. (MAIA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
MAIA remains a development-stage business: operations produced no reported revenue while losses required repeated external financing.
FY2025 R&D was$0.5M versus$10.0M in FY2024, yet operating cash outflow reached$18.8M and operating loss reached$24.3M . That combination suggests the spending profile changed rather than the business becoming less cash-intensive.
The financing structure became more leveraged: debt-to-equity rose from 1.8x to 3.1x between FY2024 and FY2025, while the current ratio fell from 2.7x to 1.7x. With liabilities of
FY2025 financing inflows of
Financial Health Signals
MAIA Biotechnology, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
MAIA Biotechnology, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
MAIA Biotechnology, Inc. reported a net loss of $22.4M while operations used $18.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
MAIA Biotechnology, Inc. reported -$7.9M in net income in Q2 2026. This represents a decrease of 48.6% from the same quarter a year earlier. Against the prior quarter it is down 24.7%.
MAIA Biotechnology, Inc. earned -$0.13 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 7.1%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
MAIA Biotechnology, Inc. held $0 in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
MAIA Biotechnology, Inc.'s ROE was -38.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 99.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 15.5 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
MAIA Biotechnology, Inc. invested $5.6M in research and development in Q2 2026. This represents an increase of 81.3% from the same quarter a year earlier. Against the prior quarter it is up 12819.9%.
Not reported for Q2 2026.
Not reported for Q2 2026.
MAIA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $5.6M+81.3% | $44K-98.6% | N/A | $6.4M+138.4% | $3.1M+51.6% | $3.2M+37.8% | N/A | $2.7M+2.6% |
| SG&A Expenses | $2.7M+30.3% | $3.4M+53.7% | N/A | $3.0M+97.4% | $2.1M+16.6% | $2.2M+36.8% | N/A | $1.5M-35.4% |
| Operating Income | -$8.3M-61.0% | -$6.9M-28.1% | N/A | -$9.4M-123.5% | -$5.2M-35.4% | -$5.4M-37.4% | N/A | -$4.2M+15.5% |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $85+8400.0% |
| Income Tax | N/A | $339 | N/A | N/A | N/A | $0 | N/A | N/A |
| Net Income | -$7.9M-48.6% | -$6.4M-41.0% | N/A | -$8.9M-225.4% | -$5.3M+39.8% | -$4.5M+44.0% | N/A | -$2.7M+43.9% |
| EPS (Basic) | -$0.13+27.8% | -$0.14+12.5% | -$0.08+33.3% | -$0.27-145.5% | -$0.18+55.0% | -$0.16+65.2% | -$0.12+70.7% | -$0.11+69.4% |
| EPS (Diluted) | -$0.13 | -$0.14 | -$0.08 | -$0.27-145.5% | -$0.18+55.0% | -$0.16 | -$0.12+70.7% | -$0.11 |
| Diluted Shares (Avg) | 61M | 45M | N/A | 33M+38.9% | 30M+36.5% | 28M | N/A | 24M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA.
MAIA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $28.2M+155.7% | $35.3M+197.7% | $9.7M-4.4% | $11.8M+27.5% | $11.0M-8.1% | $11.9M+36.1% | $10.2M+34.2% | $9.2M+32.0% |
| Current Assets | $28.2M+155.7% | $35.3M+197.7% | $9.7M-4.4% | $11.8M+27.2% | $11.0M-8.1% | $11.9M+36.3% | $10.2M+34.2% | $9.2M+39.3% |
| Cash & Equivalents | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $7.6M+5.5% | $7.6M+9.2% | $7.3M+12.4% | $11.7M+54.0% | $7.2M-19.1% | $6.9M-52.2% | $6.5M-8.0% | $7.6M+79.3% |
| Current Liabilities | $6.3M+24.1% | $6.3M+25.0% | $5.8M+52.4% | $10.0M+176.9% | $5.0M+43.7% | $5.1M+3.1% | $3.8M-22.4% | $3.6M-13.0% |
| Non-Current Liabilities | $1.3M-38.5% | $1.2M-33.6% | $1.5M-44.5% | $1.7M-56.5% | $2.1M-60.3% | $1.9M-80.5% | $2.7M+25.0% | $4.0M+3783.1% |
| Total Equity | $20.7M+433.3% | $27.8M+461.7% | $2.4M-34.6% | $42K-97.4% | $3.9M+22.6% | $4.9M+185.7% | $3.6M+661.2% | $1.6M-41.1% |
| Retained Earnings | -$123.9M-27.6% | -$116.0M-26.4% | -$109.6M-25.7% | -$106.0M-26.7% | -$97.1M-20.0% | -$91.8M-27.3% | -$87.2M-36.3% | -$83.7M-44.9% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
MAIA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.8M-63.2% | -$5.3M-26.4% | -$7.0M-79.6% | -$3.5M+1.1% | -$4.1M+11.7% | -$4.2M-17.2% | -$3.9M+2.1% | -$3.5M-11.6% |
| Stock-Based Compensation | $724K-9.8% | $650K+75.0% | N/A | $647K+42.1% | $802K+93.9% | $371K+6.1% | N/A | $455K-20.2% |
| Financing Cash Flow | -$65K-101.9% | $31.1M+468.6% | $4.8M-0.9% | $4.2M+575.6% | $3.4M-57.3% | $5.5M+15.8% | $4.8M-3.6% | $627K+397.7% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
MAIA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -38.4%+99.5pp | -22.9%+68.5pp | N/A | -21365.9%-21196.9pp | -137.9%+142.9pp | -91.4% | N/A | -169.0%+8.4pp |
| Return on Assets | -28.1%+20.3pp | -18.0%+20.0pp | N/A | -75.6%-46.0pp | -48.4%+25.5pp | -38.1%+54.5pp | N/A | -29.6%+40.0pp |
| Current Ratio | 4.51+2.3x | 5.59+3.2x | 1.66-1.0x | 1.18-1.4x | 2.19-1.2x | 2.35+0.6x | 2.65+1.1x | 2.56+1.0x |
| Debt-to-Equity | 0.37-1.5x | 0.27-1.1x | 3.08+1.3x | 281.75+277.0x | 1.85-1.0x | 1.40 | 1.79-13.1x | 4.71+3.2x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| MAIA Biotechnology, Inc. MAIA | FY2025 | N/A | -$22.4M | N/A | $67.9M | — |
| Cue Biopharma, Inc. CUE | FY2025 | $27.5M | -$26.6M | -96.9% | $135.6M | 63/100 |
| PDS Biotechnology Corporation PDSB | FY2025 | N/A | -$34.5M | N/A | $94.2M | — |
| BioXcel Therapeutics, Inc. BTAI | FY2025 | $642K | -$69.9M | N/A | $2.3M | — |
| Artiva Biotherapeutics, Inc. ARTV | FY2025 | $0 | -$83.9M | N/A | $296.3M | — |
| Quantum Biopharma Ltd. QNTM | FY2025 | N/A | N/A | N/A | $21.9M | — |
Where MAIA Biotechnology, Inc. Ranks
Frequently Asked Questions
Is MAIA Biotechnology, Inc. profitable?
No, MAIA Biotechnology, Inc. (MAIA) reported a net income of -$22.4M in fiscal year 2025.
What is MAIA Biotechnology, Inc.'s return on equity (ROE)?
MAIA Biotechnology, Inc. (MAIA) has a return on equity of -942.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is MAIA Biotechnology, Inc.'s operating cash flow?
MAIA Biotechnology, Inc. (MAIA) recorded an outflow of $18.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are MAIA Biotechnology, Inc.'s total assets?
MAIA Biotechnology, Inc. (MAIA) had $9.7M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does MAIA Biotechnology, Inc. spend on research and development?
MAIA Biotechnology, Inc. (MAIA) invested $454K in research and development during fiscal year 2025.
What is MAIA Biotechnology, Inc.'s current ratio?
MAIA Biotechnology, Inc. (MAIA) had a current ratio of 1.66 as of fiscal year 2025, which is generally considered healthy.
What is MAIA Biotechnology, Inc.'s debt-to-equity ratio?
MAIA Biotechnology, Inc. (MAIA) had a debt-to-equity ratio of 3.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is MAIA Biotechnology, Inc.'s return on assets (ROA)?
MAIA Biotechnology, Inc. (MAIA) had a return on assets of -230.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is MAIA Biotechnology, Inc.'s P/E ratio?
MAIA Biotechnology, Inc. (MAIA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $67.9M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is MAIA Biotechnology, Inc.'s price-to-sales ratio?
MAIA Biotechnology, Inc. (MAIA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $67.9M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does MAIA Biotechnology, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, MAIA Biotechnology, Inc. (MAIA) held $0 in cash, cash equivalents and investments, and reported an operating cash outflow of $18.8M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is MAIA Biotechnology, Inc.'s Piotroski F-Score?
MAIA Biotechnology, Inc. (MAIA) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are MAIA Biotechnology, Inc.'s earnings high quality?
MAIA Biotechnology, Inc. (MAIA) reported a net loss of $22.4M while operations used $18.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.